US Denials Of HCV Treatment Coverage Rising, Regardless Of Payer Type
Executive Summary
Trio Health data covering 15,000 patients over three years reveals that 29% of patients failed to start prescribed HCV treatment in 2016, up from 8% in 2104. The "non-starts" appear partially due to denials of coverage by payers and not even the sickest patients have been shielded.
You may also be interested in...
CMS Wants To Facilitate Value-Based Discounts For HCV Drugs In Medicaid
CMS requests information from hepatitis C manufacturers on how value-based purchasing arrangements might work in Medicaid. Agency also urges state Medicaid directors to relax overly strict coverage requirements for the drugs.
Deal Watch: Six Small Biopharma Mergers Reflect Recent Trend
M&A edition: Mergers by Century/Clade, Eliem/Tenet, Kintara/TuHURA, Aditxt/Appili, Onconova/Traws and Apotex/Searchlight follow other companies joining forces in a tight cash environment.
Roche Gets Adjuvant ALK+ Lung Cancer To Itself With Alecensa Approval
The US FDA cleared Roche’s supplemental approval request for ALK inhibitor Alecensa in ALK-positive non-small cell lung cancer following tumor resection.